• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Alnylam and Monsanto form strategic alliance

Alnylam and Monsanto form strategic alliance

August 28, 2012
CenterWatch Staff

St. Louis-based Monsanto and Alnylam Pharmaceuticals of Cambridge, Mass., have formed a strategic alliance to advance biological technologies in the field of agriculture. The new alliance brings Alnylam's broad RNAi-based intellectual property (IP) and proprietary technologies to Monsanto's new BioDirect technology, which aims to deliver innovative biological solutions for farmers.

Monsanto will receive worldwide, exclusive rights to use Alnylam's platform technology and IP in the field of agriculture, including the ability to grant sublicenses. Monsanto will pay Alnylam $29.2 million up front. In addition, Alnylam is eligible to receive milestone payments and additional funding for collaborative research efforts, and royalty payments on products utilizing Alnylam technology and IP. Monsanto becomes Alnylam's strategic partner in agriculture for a 10-year period.

"We believe biological products have great promise in agriculture, and we are excited to be collaborating with Alnylam in this area," said Tom Adams, vice president of chemistry technology at Monsanto.

"This new alliance furthers our vision for RNAi technologies across a broad range of applications and is representative of our passion to pioneer these new frontiers,” said Rachel Meyers, Ph.D., vice president, research and RNAi lead development at Alnylam. “While we remain focused on the advancement of RNAi therapeutics as a new class of innovative medicines—and, specifically our 'Alnylam 5x15' product strategy—this collaboration with Monsanto enables broader uses of Alnylam intellectual property and technologies for additional value creation."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing